Article
Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.
Anticancer research - 1 Oct 2010
Fukazawa Takuya, Maeda Yutaka, Matsuoka Junji, Yamatsuji Tomoki, Shigemitsu Kaoru, Morita Ichiro, Faiola Francesco, Durbin Mary L, Soucek Laura, Naomoto Yoshio
Abstract excerpt
Myc is an oncogenic transcription factor that promotes tumorigenesis. Recently, a dominant negative form of Myc (Omomyc) was shown to cause regression of lung tumors in a mouse model of lung cancer caused by KRAS mutation, suggesting that Myc might be a potential therapeutic target to treat the K...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.